Study shows greater clinical improvement compared to standard of care metronidazole with favorable tolerability
MIAMI BEACH, Florida., March 20, 2026 /PRNewswire/ — Crescel LLC, an innovative science and technology company, today announced results from a double-blind, randomized, active-controlled clinical trial evaluating its biobotanical skin renewal cream against a commonly used standard of care: topical metronidazole (Metrocream®) combined with CeraVe® moisturizing – in people with rosacea, a chronic inflammatory skin disease.
The study, conducted under the leadership of a world-renowned dermatologist, recruited 60 adult subjects with mild to severe rosacea and evaluated results over a 12-week treatment period. The trial results are expected to be submitted for publication in a peer-reviewed medical journal in 2026.
Clinical results
Subjects were randomized to receive either Crescel Skin Renewal Cream or metronidazole 0.75% plus moisturizer twice daily. Dermatological assessments were performed at baseline and at weeks 4, 8 and 12.
Crescel Skin Renewal Cream demonstrated statistically significant improvements over baseline in key metrics:
- Redness (erythema):
- Crescel: ↓54% at week 12 (p<0.001)
- Standard of care: ↓23% at week 12 (p=0.004)
- Inflammatory lesions (papules and pustules):
- Crescel: ↓74% at week 8, maintained until week 12 (p≤0.004)
- Standard of care: ↓17% at week 12 (not statistically significant)
Both groups showed a reduction in redness; however, the Crescel group demonstrated greater overall improvement. For inflammatory lesions, the reductions observed in the comparator group did not reach statistical significance at any time point.
Tolerance
Crescel Skin Renewal Cream was well tolerated, with no negative side effects observed during the study period. No clinically relevant issues related to irritation, dryness, or skin barrier disruption have been reported.
Product profile
Crescel Skin Renewal Cream is formulated as a biobotanical topical, combining naturally derived components with a proprietary microemulsion delivery system designed to support healthy skin function. The product has received the National Rosacea Society Seal of Acceptance and the National Psoriasis Foundation Seal of Recognition.
“These results support the potential for a new approach in the management of rosacea,” said Peter J. Passalacqua, Jr., co-founder, chairman and CEO of Crescel. “In this controlled clinical trial, Crescel demonstrated greater improvement in key metrics compared to a commonly used standard treatment regimen, with a favorable tolerability profile. »
Additional comments
Crescel Skin Renewal Cream has also been evaluated in other skin conditions, including psoriasis, eczema, acne and diabetic ulcers.
“Crescel’s healing abilities are exceptional,” said Dr. Roberta Shapiro, Department of Regenerative Medicine and Rehabilitation, Columbia University Medical Center and Crescel’s senior medical advisor. “I have never seen anything like this in my 30 years of practicing rehabilitation medicine.”
Crescel Skin Renewal Cream is available online at www.crescel.com.
Show original content:https://www.prnewswire.com/apac/news-releases/crescel-reports-positive-randomized-controlled-trial-results-for-biobotanical-skin-renewal-cream-in-rosacea-302719269.html
SOURCE Crescel LLC
